Trial
NCT04544410
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Spruce Biosciences
Collaborators
—
Condition
Congenital Adrenal Hyperplasia
Intervention
Tildacerfont/Placebo
Why stopped
Study did not meet its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-01